Novartis plans to spin off its generics unit Sandoz as part of an effort to focus on its innovative pharmaceuticals.   This past October the company began a strategic review of Sandoz, exploring options including spinning it out, selling it or keeping the business as is. To date Novartis has not received any formal binding offers and according to the company has determined the spin of is the best way to separate the two companies.   Sandoz sales were flat at $9.6 billion last year. Sandoz se...